

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Chaoju Eye Care Holdings Limited

朝聚眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2219)

(I) INTERIM RESULTS ANNOUNCEMENT

FOR THE SIX MONTHS ENDED JUNE 30, 2025; AND

(II) UPDATED EXPECTED TIMETABLE FOR USE OF PROCEEDS AND CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING

FINANCIAL AND OPERATIONAL HIGHLIGHTS

Revenue of the Group decreased by 4.9% to RMB698.3 million for the six months ended June 30, 2025 from RMB734.3 million for the same period in 2024.

Gross profit of the Group decreased by 11.4% to RMB297.7 million for the six months ended June 30, 2025 from RMB336.0 million for the same period in 2024. Gross profit margin decreased to 42.6% for the six months ended June 30, 2025 from 45.8% for the same period in 2024.

Profit before tax of the Group decreased by 14.8% to RMB153.1 million for the six months ended June 30, 2025 from RMB179.6 million for the same period in 2024. Pre-tax profit margin decreased to 21.9% for the six months ended June 30, 2025 from 24.5% for the same period in 2024.

Net profit of the Group decreased by 17.1% to RMB110.7 million for the six months ended June 30, 2025 from RMB133.6 million for the same period in 2024. Net profit margin decreased to 15.9% for the six months ended June 30, 2025 from 18.2% for the same period in 2024.

Non-IFRS adjusted net profit⁽¹⁾ of the Group decreased by 18.2% to RMB118.4 million for the six months ended June 30, 2025 from RMB144.8 million for the same period in 2024. Non-IFRS adjusted net profit margin for the six months ended June 30, 2025 and the six months ended June 30, 2024 were 17.0% and 19.7%, respectively.

Basic earnings per Share of the Group decreased by 17.2% to RMB0.16 for the six months ended June 30, 2025 from RMB0.20 for the same period in 2024.

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2025 (for the six months ended June 30, 2024: HK\$0.1307).

NON-IFRS MEASURES

To supplement the Group's condensed consolidated financial statements which are presented in accordance with IFRS, the Company has provided non-IFRS adjusted net profit⁽¹⁾, non-IFRS adjusted net profit margin, non-IFRS EBITDA and non-IFRS adjusted EBITDA as non-IFRS measures, which are not required by, or presented in accordance with, IFRS. The Company believes that the non-IFRS adjusted financial measures provide useful information to investors and others in understanding and evaluating the Group's condensed consolidated statements of profit or loss in the same manner as they helped the Company's management, and that the Company's management and investors may benefit from referring to these non-IFRS adjusted financial measures in assessing the Group's operating performance from period to period by eliminating impacts of items that the Group does not consider indicative of the Group's operating performance. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS adjusted results on a stand-alone basis or as a substitute for results under IFRS.

Note:

- (1) Non-IFRS adjusted net profit for the six months ended June 30, 2025 and 2024 was calculated as net profit excluding share-based compensation expenses.

SUMMARY OF UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended June 30, 2025

| | Unaudited | |
|--|---------------------------|-----------|
| | Six months ended June 30, | |
| | 2025 | 2024 |
| | (RMB'000) | (RMB'000) |
| Revenue | 698,258 | 734,287 |
| Cost of sales | (400,591) | (398,313) |
| Gross profit | 297,667 | 335,974 |
| Other income and gains | 37,833 | 25,674 |
| Selling and distribution expenses | (48,755) | (62,976) |
| Administrative expenses | (102,167) | (106,437) |
| Impairment losses on financial assets at amortised cost, net | (353) | (534) |
| Other expenses | (25,031) | (6,443) |
| Finance costs | (6,104) | (5,618) |
| Profit before tax | 153,090 | 179,640 |
| Income tax expense | (42,351) | (46,020) |
| Net profit | 110,739 | 133,620 |
| Non-IFRS adjusted net profit ⁽¹⁾ | 118,401 | 144,753 |
| Gross profit margin | 42.6% | 45.8% |
| Net profit margin | 15.9% | 18.2% |
| Non-IFRS adjusted net profit margin ⁽²⁾ | 17.0% | 19.7% |
| Non-IFRS EBITDA ⁽³⁾ | 210,165 | 234,818 |
| Non-IFRS adjusted EBITDA | 217,827 | 245,951 |

Notes:

- (1) Adjustments to the net profit for the six months ended June 30, 2025 and 2024 include share-based compensation expenses.
- (2) Non-IFRS adjusted net profit margin was calculated based on non-IFRS adjusted net profit divided by revenue.
- (3) Non-IFRS EBITDA represents profit before tax excluding (i) finance costs; (ii) interest income and fair value gains on financial assets at fair value through profit or loss; (iii) depreciation of property, plant and equipment; (iv) depreciation of investment properties; (v) amortisation of intangible assets; and (vi) depreciation of right-of-use assets.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review

The Group is a leading ophthalmic medical service group in North China with a strong reputation nationwide. The Group was founded in 1988 in Baotou, Inner Mongolia, as a clinic providing ophthalmic services. Since its inception, the Group adheres to the vision of “Being a Leader of Happy Ophthalmic Healthcare” (成為全球快樂眼健康引領者) and has been providing patients with “Safe, Effective and Friendly Ophthalmic Medical Experience” with the aid of effective medical equipment and technology as well as professional, caring and considerate services.

As at June 30, 2025, the Group operated a network of 31 ophthalmic hospitals and 29 optical centers spanning across a total of 7 provinces, municipalities and autonomous regions in China. The ophthalmic hospitals specialize in providing ophthalmic services and the optical centers offer a series of optical products and services to satisfy a wide array of requests from customers.

The following table sets forth a breakdown of certain operational information by type of services provided by the Group for the periods indicated:

| | Unaudited | |
|---|----------------------------------|-------------|
| | Six months ended 30 June, | |
| | 2025 | 2024 |
| The hospitals | | |
| Out-patient services | | |
| Number of out-patient visits | 522,051 | 571,087 |
| Average spending per visit (RMB) ⁽²⁾ | 797 | 764 |
| In-patient services | | |
| Number of in-patient admissions | 34,844 | 35,814 |
| Average spending per admission (RMB) ⁽²⁾ | 6,688 | 7,052 |
| Optical centers | | |
| Number of customer visits ⁽¹⁾ | 48,804 | 51,774 |
| Average selling price (RMB) ⁽²⁾ | 978 | 868 |

Notes:

- (1) Represents the total number of purchases made by customers at the optical centers. If a customer makes more than one purchase at the optical centers within the same day, he/she will only be counted once. If a customer purchases at the optical centers on different days, he/she will be counted according to the number of days he/she made purchases at the optical centers.
- (2) Subject to rounding adjustments, (i) average spending per visit/admission represents the average spending per visit/admission calculated by the total revenue generated from the out-patient or in-patient services (as applicable) divided by the total number of out-patient or in-patient visit/admission (as applicable); and (ii) average selling price represents the average selling price calculated by the total revenue generated from the optical centers divided by the total number of customer visits.

The Group's revenue decreased by 4.9% from RMB734.3 million for the six months ended June 30, 2024 to RMB698.3 million for the six months ended June 30, 2025, primarily due to (1) slightly decrease in outpatient visits and inpatient admissions mainly in basic ophthalmic services; and (2) pricing adjustments starting from the second half of 2024 within the Group in response to intensified market competition and China's national policy of Volume-Based Procurement (VBP).

The following table sets forth a breakdown of revenue by business segments for the periods indicated:

| | Unaudited | | | |
|--|----------------------------------|----------------------|-----------------------|----------------------|
| | Six months ended June 30, | | | |
| | 2025 | | 2024 | |
| | Revenue | Percentage | Revenue | Percentage |
| | (RMB'000) | of revenue | (RMB'000) | of revenue |
| Consumer ophthalmic services | 359,492 | 51.5% | 376,483 | 51.3% |
| Basic ophthalmic services | 337,467 | 48.3% | 357,214 | 48.6% |
| Sales of equipment and medical consumables | 1,299 | 0.2% | 590 | 0.1% |
| Total | <u>698,258</u> | <u>100.0%</u> | <u>734,287</u> | <u>100.0%</u> |

Consumer ophthalmic services

The Group's consumer ophthalmic services include treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia prevention and control, dry eye syndrome, oculoplastic and provision of optical products and services, the costs for which are currently not covered by public health insurance programs.

To maintain the Group's strong reputation in the provision of consumer ophthalmic services, the Group (i) optimized its marketing and promotion activities with a focus on online promotion, new media and other online channels; (ii) chaired various pro bono eye disease screening activities for the public; (iii) formulated operational management measures to optimize its customer membership management model for maintaining customer loyalty; and (iv) streamlined the admission process to increase the Group's capacity for patient visits. The Group continued to reinforce the training on consumer ophthalmic services techniques and related skills and improve the service quality in adherence to the Group's core values of "provide patients with "Safe, Effective and Friendly Ophthalmic Medical Services". Furthermore, the Group also implemented stringent medical quality control measures and upgraded equipment technology to provide patients with high-quality medical services and enhance the Group's reputation.

In addition, the pricing of consumer ophthalmic services provided by designated hospitals operated by the Group is subject to policy constraints under the Guidelines for the Establishment of Pricing Items for Ophthalmology Medical Services (Trial) with respect to consumer ophthalmology services, while the consumer ophthalmic services provided by other entities operated by the Group are not subject to pricing guidance from public health insurance authorities, whereby the Group retains greater pricing flexibility. The extent of autonomy has enabled the Group to allocate more resources toward driving long-term and sustained growth in consumer ophthalmology services. For the six months ended June 30, 2025, the Group's consumer ophthalmic services contributed to 51.5 % of the Group's total revenue. In terms of revenue, consumer ophthalmic services have continued to be the Group's major source of revenue.

Basic ophthalmic services

The Group's basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, the cost of which are partially eligible to be covered by public health insurance programs.

The Group continued to devote significant resources on the procurement of cutting-edge ophthalmic equipment and expand its use of advanced treatment options. This commitment includes the deployment of femtosecond laser-assisted cataract surgery (FLACS) equipment, as well as high-end diagnostic imaging systems and premium consumables. These strategic investments have elevated procedural quality and patient safety, driving stronger satisfaction and higher return rates for our basic ophthalmology services across all our hospitals.

For the six months ended June 30, 2025, the Group's basic ophthalmic services accounted for 48.3% of the Group's total revenue, being another major source of revenue of the Group.

Gross Profit and Gross Profit Margin

The following table sets forth a breakdown of gross profit by business segments and the corresponding gross profit margin for the periods indicated:

| | Unaudited | | | |
|--|---------------------------|---------------------|----------------|---------------------|
| | Six months ended June 30, | | 2024 | |
| | 2025 | | 2024 | |
| | Gross profit | Gross profit margin | Gross profit | Gross profit margin |
| | (RMB'000) | | (RMB'000) | |
| Consumer ophthalmic services | 150,125 | 41.8% | 183,025 | 48.6% |
| Basic ophthalmic services | 147,413 | 43.7% | 152,892 | 42.8% |
| Sales of equipment and medical consumables | 129 | 9.9% | 57 | 9.7% |
| Total | <u>297,667</u> | <u>42.6%</u> | <u>335,974</u> | <u>45.8%</u> |

The gross profit generated from consumer ophthalmic services was RMB150.1 million for the six months ended June 30, 2025, representing a decrease of 18.0% compared to the six months ended June 30, 2024, primarily due to the heightened industry competition, which compressed the profit margin and led to a decline in the segment's gross margin. The gross profit generated from basic ophthalmic services was RMB147.4 million for the six months ended June 30, 2025, representing a decrease of 3.6% compared to the six months ended June 30, 2024, primarily due to (1) tightened national medical insurance policy and settlements; and (2) increased profit margins from enhanced deployment of FLACS and other equipment and technology to supplement basic ophthalmic services, offsetting the loss of profits resulting from China's VBP. The Group's gross profit was RMB297.7 million for the six months ended June 30, 2025, representing a decrease of 11.4% compared to the six months ended June 30, 2024.

Team of Medical Professionals

The Group has a deep bench of ophthalmic experts with medical expertise and rich experience to treat a wide range of eye diseases and to provide various types of consumer ophthalmic services. The Group focuses on the quality of ophthalmic services and devotes resources to allow its ophthalmologists to provide ophthalmic medical services in a professional, dedicated and responsible manner. The Group is also committed to recruiting and cultivating qualified professionals to form an ophthalmic medical team with outstanding professional and ethical standards and strong sense of responsibility. As of June 30, 2025, the Group had a total of 1,500 full-time medical professionals (as of June 30, 2024: 1,458), including 320 physicians, 631 nurses and 549 other professionals (as of June 30, 2024: 302 physicians, 622 nurses and 534 other professionals). Among the 320 physicians, 271 are full-time physicians registered as specialized ophthalmologists. In addition, the Group also had 74 multi-site practice physicians who were full-time employees of other medical institutions.

Awards, Recognitions and Social Responsibility

In 2025, the Group has received recognitions and awards at different levels and from different aspects, such as:

| | |
|---------------|---|
| January 2025 | Baotou City Chaoju Eye Hospital Co., Ltd.* (包頭市朝聚眼科醫院有限公司) was awarded as “High-Growth Leading Enterprise (高效成長領軍企業)” |
| February 2025 | Chaoju (Chifeng) Eye Hospital Co., Ltd. (朝聚(赤峰)眼科醫院有限公司) was awarded as “Model Enterprise of Integrity (誠信示範企業)” |
| March 2025 | Baotou City Chaoju Eye Hospital Co., Ltd.* (包頭市朝聚眼科醫院有限公司) received the “Outstanding Unit (Collective) for Medical Service Capacity Enhancement in Jiuyuan District Health System for the Year 2024* (九原區衛生健康系統2024年度醫療服務能力提升突出單位(集體))” honorary title |
| May 2025 | Tongliao Chaoju Eye Hospital Co., Ltd.* (通遼朝聚眼科醫院有限公司) was recognized as “Special Contribution Enterprise for Employment of Graduates from Tongliao Vocational College (通遼職業學院畢業生就業工作特殊貢獻企業)” and “Industry-Education Integration Training Base (產教融合實訓基地)” |

June 2025

Chaoju (Inner Mongolia) Eye Hospital Co., Ltd.* (朝聚(內蒙古)眼科醫院有限公司)) and Baotou City Chaoju Eye Hospital Co., Ltd.* (包頭市朝聚眼科醫院有限公司) were rated as Grade 3A specialized hospitals (三級甲等專科醫院)

Chifeng Chaoju Eye Hospital* (赤峰朝聚眼科醫院) was rated as a Grade 3B hospital (三級乙等醫院)

Chaoju Eye Care Science Museum’s exhibit “The Legend of Bright Eyes (明眸正傳)” won the third prize in the National Eye Health Science Popularization Competition (全國眼健康科普大賽)

Chaoju (Ulanqab) Eye Hospital Co., Ltd.* (朝聚(烏蘭察布)眼科醫院有限公司) received the “National Civilized Unit (全國文明單位)” honorary title

July 2025

Hangzhou Chaoju Eye Hospital Co., Ltd.* (杭州朝聚眼科醫院有限公司) was selected as a member unit of China Ophthalmic Innovation Technology Science Popularization Alliance* (中國眼科創新技術科普聯盟單位)

The Group provides charitable medical aid and medical consultations to public institutions and disadvantaged communities from time to time. Such charitable events allow the Company to maintain good relationships with government authorities and institutions while simultaneously promote its ophthalmic and optical services. These events do not only benefit the disadvantaged communities, but also improve the Group’s brand awareness and reputation. For example, in the first half of 2025, the Group:

1. continued to participate in the “Spread the Love in Inner Mongolia, Helping Patients in Pursuit of Health and Dreams” (大愛北疆助康圓夢) charity campaign jointly organized by the Inner Mongolia Disabled Persons’ Federation and Inner Mongolia Disabled Persons’ Welfare Foundation to provide eye examination and treatment services for vulnerable groups;
2. continued to participate in the “Belt and Road: Bright Tour” public welfare project in the China-Mongolia, provided training for optometrists in Mongolia and performed cataract recovery operation services for cataract patients in Mongolia;
3. provided optical screening services to and established medical profiles for primary and secondary school students in Inner Mongolia;

4. provided professional and customized rehabilitation training for children with low vision and squint, and carried out prevention activities to educate children and parents for early diagnosis;
5. conducted various forms of online and offline expert science popularization lectures on eye health for students and their parents for enriching their knowledge in eye health and common eye diseases among children; and
6. led 2 scientific research projects with various authorities and published 3 articles on reputable scientific journals, and published 1 article domestically.

BUSINESS PROSPECTS AND STRATEGIC HIGHLIGHTS

The demand for ophthalmic medical services has gradually increased in recent years and is expected to remain relatively steady growth rates in the foreseeable future as a result of continued economic growth and an increasingly aging population. However, ophthalmic medical resources in China are scarce, and the penetration rate of surgeries for eye diseases in China is low.

As at the date of this announcement, the Group operated a network of 31 ophthalmic hospitals and 29 optical centers. The Group plans to continue expanding its network layout and strengthening its network coverage in the key regions of North China and expects to acquire more hospitals in the coming future. The Group also plans to expand its layout in the key regions of Yangtze River Delta region through acquisitions and establishment of new hospitals and optical centers. As at the date of this announcement, the Group had not entered into any letters of intent or agreements with respect to acquisitions and had not identified any definite acquisition targets.

As a leading ophthalmic medical services group in China, the Group is able to leverage on its branding and market reputation in North China and continue to increase its market share in North China. The Group has further enhanced its brand awareness and reputation in East China through continuously expanding its market share and consolidating the Group's market position in the region. The Group is well-positioned to capture the significant growth potential of the underserved market of private ophthalmic services in China.

Looking into the future and the second half of 2025, the Group expects to:

1. adhere to the vision of “Being a Leader of Happy Ophthalmic Healthcare” to provide effective medical services and continuously revise its improvement plans and promote “Happy Action” plans;
2. reinforce its leading position in North China and enhance its market positioning in Yangtze River Delta region and other key regions while developing its featured ophthalmic hospitals, new-build and mergers and acquisitions in key regions;
3. seize opportunities in the consumer ophthalmic market and expand consumer ophthalmology by leveraging Chaoju Eye ophthalmic’s clinical expertise in ophthalmology diagnosis and treatment in order to become a national chain provider of ophthalmic services trusted by the public;
4. improve the utilization efficiency of its regional resources and strengthen its centralized management model with regional center hospitals as the core;
5. serve with quality medical services and continuously improve patient satisfaction and brand awareness;
6. continue to promote Golocal Talent Program, actively attract and recruit talents by further refining its training and career developments programs, cultivating its unique corporate culture and offering fair incentives to its key employees;
7. standardize the management of the Group and the communication with regulatory authorities, such as the Stock Exchange, and various professional institutions, so as to improve the comprehensive corporate governance;
8. deepen the application of intelligent technologies and leverage artificial intelligence to enhance our work efficiency; and
9. continue to promote the construction of a sound environmental, social and corporate governance (ESG) system and constantly give back to the society.

Financial Review

Revenue

During the Reporting Period, the Group generated revenue primarily from providing (i) consumer ophthalmic services and (ii) basic ophthalmic services. The revenue of the Group decreased by 4.9% from RMB734.3 million for the six months ended June 30, 2024 to RMB698.3 million for the six months ended June 30, 2025.

Consumer ophthalmic services

The Group's consumer ophthalmic services offer a variety of ophthalmic disorder treatments and prevention measures, including myopia control, refractive correction (including presbyopia correction), dry eye syndrome, oculoplastic and provision of optical products and services.

The Group's revenue from consumer ophthalmic services decreased by 4.5% from RMB376.5 million for the six months ended June 30, 2024 to RMB359.5 million for the six months ended June 30, 2025, primarily due to pricing adjustments in response to intensified market competition especially in refractive operation.

Basic ophthalmic services

The Group's basic ophthalmic services offer a wide range of common eye diseases treatments, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases.

The Group's revenue from basic ophthalmic services decreased by 5.5% from RMB357.2 million for the six months ended June 30, 2024 to RMB337.5 million for the six months ended June 30, 2025, primarily due to (1) slightly decrease in outpatient visits and inpatient admissions; and (2) a combined impact of pricing adjustments starting from the second half of 2024 for the implementation of China's VBP and the enhanced deployment of FLACS and other equipment and technology to supplement basic ophthalmic services.

Cost of Sales

During the Reporting Period, the Group's cost of sales was primarily composed of medical consumables and optical products, employee compensation directly related to the Group's provision of medical services, cost of pharmaceuticals, depreciation, amortization and rental expenses.

The Group's cost of sales increased by 0.6% from RMB398.3 million for the six months ended June 30, 2024 to RMB400.6 million for the six months ended June 30, 2025, primarily due to increase in procedures and surgeries in refractive operation and cataract recovery operation. This growth in case volume, in turn, has contributed to a small rise in the costs associated with medical consumables and pharmaceuticals.

Gross Profit and Gross Profit Margin

The Group's gross profit decreased by 11.4% from RMB336.0 million for the six months ended June 30, 2024 to RMB297.7 million for the six months ended June 30, 2025.

The Group's gross profit margin decreased from 45.8% for the six months ended June 30, 2024 to 42.6% for the six months ended June 30, 2025. The decrease in gross profit margin was primarily due to pricing adjustments starting from the second half of 2024 in response to intensified market competition and implementation of VBP.

Other Income and Gains

During the Reporting Period, the Group's other income and gains primarily comprised interest income, fair value gains and government grants.

The Group's other income and gains increased by 47.1% from RMB25.7 million for the six months ended June 30, 2024 to RMB37.8 million for the six months ended June 30, 2025, primarily due to (i) obtaining certain governmental subsidies; and (ii) an increase in fair value gains from financial assets at fair value through profit or loss.

Selling and Distribution Expenses

During the Reporting Period, the Group's selling and distribution expenses were primarily composed of the compensation of the Group's sales and marketing personnel, advertising expenses, depreciation, amortization, office expenses and rental expenses.

The Group's selling and distribution expenses decreased by 22.5% from RMB63.0 million for the six months ended June 30, 2024 to RMB48.8 million for the six months ended June 30, 2025, primarily due to the reduction of inefficient advertising expenditures through precise targeting and efficient utilization of advertising resources, while maintaining stable advertising effectiveness.

Administrative Expenses

During the Reporting Period, the Group's administrative expenses were primarily composed of the compensation of and share-based payments to the Group's administrative and management personnel, depreciation and amortization, rental expenses and fees paid for the professional services and office expenses.

The Group's administrative expenses decreased by 3.9% from RMB106.4 million for the six months ended June 30, 2024 to RMB102.2 million for the six months ended June 30, 2025, primarily due to (1) the conclusion of the amortization period for share-based incentive bonuses for certain management personnel; and (2) strict control expenditures such as business entertainment and travel.

Other Expenses

During the Reporting Period, the Group's other expenses were primarily composed of impairment losses on non-financial assets, foreign exchange losses, and other non-operating expenses. The Group's other expenses increased significantly by 290.6% from RMB6.4 million for the six months ended June 30, 2024 to RMB25.0 million for the six months ended June 30, 2025. This increase in other expenses was primarily due to impairment of goodwill and intangible assets at certain hospitals with under-performing operational results.

Impairment losses on financial assets at amortised cost, net

During the Reporting Period, the Group's impairment losses on financial assets at amortised cost were primarily composed of provision for impairment losses on trade receivables and other receivables.

The Group's impairment losses on financial assets at amortised cost were RMB0.5 million for the six months ended June 30, 2024 and RMB0.4 million for the six months ended June 30, 2025, which remained relatively stable.

Finance Costs

During the Reporting Period, the Group's finance costs were primarily composed of interest expenses on lease liabilities.

The Group's finance costs were RMB5.6 million for the six months ended June 30, 2024 and RMB6.1 million for the six months ended June 30, 2025, which remained relatively stable.

Income Tax Expense

During the Reporting Period, the income tax rate generally applicable to the Group's subsidiaries in China is 25% and certain subsidiaries of the Group are eligible for a preferential income tax rate of 15%. Certain other subsidiaries are eligible for a preferential income tax rates of 3% or 5% with respect to part of their taxable income.

The Group's income tax expenses decreased by 7.8% from RMB46.0 million for the six months ended June 30, 2024 to RMB42.4 million for the six months ended June 30, 2025, primarily due to a decrease in the profit before tax.

Net Profit and Net Profit Margin

As a result of the foregoing, the Group's net profit decreased by 17.1% to RMB110.7 million for the six months ended June 30, 2025 from RMB133.6 million for the six months ended June 30, 2024. The Group's net profit margin decreased to 15.9% for the six months ended June 30, 2025 from 18.2% for the same period in 2024. The Group defined non-IFRS adjusted net profit as profit for the period adjusted for items which are non-recurring or extraordinary, including share-based compensation expenses. The Group's non-IFRS adjusted net profit decreased by 18.2% to RMB118.4 million for the six months ended June 30, 2025 from RMB144.8 million for the same period in 2024.

Non-IFRS Measures

To supplement the Group's condensed consolidated financial statements which are presented in accordance with IFRS, the Company has provided non-IFRS adjusted net profit, non-IFRS adjusted net profit margin, non-IFRS EBITDA and non-IFRS adjusted EBITDA as non-IFRS measures, which are not required by, or presented in accordance with, IFRS. The Company believes that the non-IFRS adjusted financial measures provide useful information to investors and others in understanding and evaluating the Group's condensed consolidated statements of profit or loss in the same manner as they helped the Company's management, and that the Company's management and investors may benefit from referring to these non-IFRS adjusted financial measures in assessing the Group's operating performance from period to period by eliminating impacts of items that the Group does not consider indicative of the Group's operating performance. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS adjusted results on a stand-alone basis or as a substitute for results under IFRS.

The following table sets forth the reconciliations of the Group's non-IFRS financial measures for the six months ended June 30, 2024 and 2025 to the nearest measures prepared in accordance with IFRS:

| | Unaudited | |
|--|---------------------------------|------------------|
| | Six months ended June 30 | |
| | 2025 | 2024 |
| | (RMB'000) | (RMB'000) |
| Net Profit | 110,739 | 133,620 |
| Adjustments: | | |
| Share-based compensation expenses | 7,662 | 11,133 |
| Non-IFRS adjusted net profit | 118,401 | 144,753 |
| Non-IFRS adjusted net profit margin | 17.0% | 19.7% |

Note:

Non-IFRS adjusted net profit margin was calculated based on non-IFRS adjusted net profit divided by revenue.

Financial Position

Trade Receivables

The Group's trade receivables decreased by 5.5% from RMB74.4 million as of December 31, 2024 to RMB70.3 million as of June 30, 2025, primarily due to a decrease in medical insurance receivables as a result of the insurance being received earlier than in the same period of 2024.

Cash and Bank Balances

The Group's business operations and expansion plans require significant amount of capital, which will be used for upgrading the existing ophthalmic hospitals and optical centers, establishing and acquiring new hospitals and other working capital requirements. The Group's principal sources of liquidity are cash generated from its business operations, as well as debt and equity financing.

| | Unaudited | |
|--|----------------------------------|------------------|
| | Six months ended June 30, | |
| | 2025 | 2024 |
| | (RMB'000) | (RMB'000) |
| Net cash flows from operating activities | 181,554 | 174,461 |
| Net cash flows used in investing activities | (579,217) | (18,791) |
| Net cash flows used in financing activities | (92,900) | (224,348) |
| Effect of foreign exchange rate changes, net | (6,432) | 975 |
| Net decrease in cash and cash equivalents | (496,995) | (67,703) |

The Group's net decrease in cash and cash equivalents is RMB497.0 million for the six months ended June 30, 2025, primarily due to net cash inflows of RMB181.6 million from operating activities, and net cash outflows of RMB579.2 million from investing activities, mainly attributable to the purchase of financial products, and net cash outflows of RMB92.9 million from financing activities, which resulted from the payment of dividends for the year ended December 31, 2024.

Trade Payables

The Group's trade payables increased by 19.6% from RMB53.6 million as of December 31, 2024 to RMB64.1 million as of June 30, 2025, primarily due to increases in payables for medical consumables and pharmaceuticals.

Other Payables and Accruals

The Group's other payables and accruals include salaries and welfare payables, rent payables, equity payables, payables for purchases of property, plant and equipment and contract liabilities.

The Group's other payables and accruals increased by 15.9% from RMB231.0 million as of December 31, 2024 to RMB267.8 million as of June 30, 2025, primarily due to an increase in payables for construction.

Contingent Liabilities

As of June 30, 2025, the Group did not have any material contingent liabilities or guarantees.

Pledge of Assets

As of June 30, 2025, bank deposits of RMB5.6 million was pledged, which are earmarked for issuing letters of guarantee to ensure the payment of migrant workers' wages in construction projects.

Capital Commitments

As of June 30, 2025, the Group had a total capital commitment of approximately RMB69.3 million (as of December 31, 2024: RMB56.4 million), primarily related to the Group's liabilities in relation to (i) the subscription of limited partnership interest in Xiamen Ronghui Hongshang Phase II Equity Investment Partnership (Limited Partnership)* (廈門融匯弘上二期股權投資合夥企業(有限合夥)); (ii) the construction and renovation of its in-network hospitals and the procurement of medical equipment; (iii) the acquisition of minority shareholders' interests in Ningbo Boshi Eye Hospital Co., Ltd. (寧波博視眼科醫院有限公司), at a total consideration of approximately RMB14.59 million; and (iv) the acquisition of equity interests in Wuzhong Yunshikang Eye Hospital Co., Ltd.* (吳忠市雲視康眼科醫院有限公司), at a total consideration of approximately RMB4.97 million.

Significant Investments

The Group subscribed for low-risk short-term structured deposit products issued by reputable commercial banks with certain portion of its temporary idle funds (including surplus cash received from its business operations and idle IPO Proceeds) for treasury management purpose in order to enhance the efficiency, the utilization of and the return on its temporary idle funds. These products are of very low risk nature with satisfactory liquidity and the Group expects that the structured deposit products will earn a better yield than current deposits generally offered by commercial banks in the PRC while at the same time offer flexibility to the Group in terms of treasury management. The Group has implemented adequate and appropriate internal control procedures to ensure subscriptions of structured deposit products would not affect the working capital or the operations of the Group, and that such investments would be closely monitored and conducted in accordance with the Group's treasury policy. As such, the Board is of the view that the subscriptions of the structured deposit products (as listed below) are fair and reasonable and are on normal commercial terms and the subscriptions are in the interests of the Company and the Shareholders as a whole.

As of June 30, 2025, the Group maintained a portfolio of structured deposit products with a total outstanding principal amount of RMB410.0 million, representing approximately 13.7% of the Group's total assets.

For the six months ended June 30, 2025, the total principal amount of the structured deposit products that the Group has subscribed for was RMB100.0 million and the amount of interest income that the Group has recognized as fair value gains on financial assets at fair value through profit or loss was approximately RMB5.0 million.

The following table sets forth a breakdown of the major structured deposit products subscribed by the Group and remain outstanding as at June 30, 2025:

| Name of the issuer of the structured deposit products | Name of the structured deposit products | Deposit starting date | Date of maturity | Principal amount of subscription ⁽¹⁾ (RMB'000) | Expected annualized return rate ⁽²⁾ | Realized/Fair value as of June 30, 2025 (RMB'000) | Percentage of the total assets of the Group as of June 30, 2025 |
|---|---|-----------------------|--------------------|--|--|--|---|
| CIB | CIB Corporate RMB Structured Deposit (興業銀行企業金融人民幣結構性存款) (CC59240806000) | August 9, 2024 | August 8, 2025 | 20,000 | 1.7000% to 2.3600% | 20,234 | 0.67% |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款(機構客戶) (CSDVY202412451) | August 13, 2024 | August 13, 2025 | 11,000 | 1.4000% to 3.1010% | 11,123 | 0.37% |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款(機構客戶) (CSDVY202412452) | August 13, 2024 | August 15, 2025 | 9,000 | 1.3960% to 3.0950% | 9,100 | 0.30% |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款(機構客戶) (CSDVY202414800) | September 30, 2024 | September 24, 2025 | 125,000 | 1.3000% to 3.1500% | 126,382 | 4.21% |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款(機構客戶) (CSDVY202414801) | September 30, 2024 | September 26, 2025 | 115,000 | 1.2950% to 3.1470% | 116,272 | 3.88% |
| CIB | CIB Corporate RMB Structured Deposit (興業銀行企業金融人民幣結構性存款) (CC59241008015) | October 10, 2024 | October 9, 2025 | 30,000 | 1.7000% to 2.3500% | 30,350 | 1.01% |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款(機構客戶) (CSDVY202508788) | June 25, 2025 | January 7, 2026 | 26,000 | 0.8000% to 2.8100% | 26,008 | 0.87% |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款(機構客戶) (CSDVY202508789) | June 25, 2025 | January 9, 2026 | 24,000 | 0.7940% to 2.8180% | 24,007 | 0.80% |

| Name of the issuer of the structured deposit products | Name of the structured deposit products | Deposit starting date | Date of maturity | Principal amount of subscription ⁽¹⁾ (RMB'000) | Expected annualized return rate ⁽²⁾ | Realized/Fair value as of | Percentage of the total assets of the Group as of |
|---|---|-----------------------|------------------|--|--|----------------------------|---|
| | | | | | | June 30, 2025 (RMB'000) | June 30, 2025 |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202508790) | June 25, 2025 | January 14, 2026 | 26,000 | 0.8000% to 2.8200% | 26,008 | 0.87% |
| BOC | BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202508791) | June 25, 2025 | January 16, 2026 | 24,000 | 0.7940% to 2.8280% | 24,007 | 0.80% |

Notes:

(1) These subscription amounts were all funded by surplus cash of the Group.

(2) Upon maturity, the Group expects to receive the principal amount together with the expected interest.

Save as disclosed in this announcement, there was no other significant investments held by the Group during the Reporting Period.

Future Plan for Material Investment and Capital Asset

The Group has entered into the construction contract with Inner Mongolia Guangxia Construction & Installation Engineering Co., Ltd. in relation to the construction of the Chaoju Eye Care Integrated Medical Complex Construction Project Phase I at a contract price of RMB222.84 million (inclusive of tax). The execution of the contract was approved by the Board on July 28, 2025. For further detail of the transaction, please refer to the announcement of the Company dated July 28, 2025.

Save as disclosed above, up to the date of this announcement, the Group did not have any future plan for material investments and capital assets.

Borrowings and Gearing Ratio

As of June 30, 2025, the Group was in a net cash position and thus, gearing ratio is not applicable.

Foreign Exchange Risk

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect its financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars, has been based on rates set by the People's Bank of China. The Group seeks to limit its exposure to foreign currency risk by closely monitoring and minimizing its net foreign currency position. During the Reporting Period, the Group did not enter into any currency hedging transactions.

Interest Rate Risk

The Group's interest rate risk arises from interest-bearing borrowings. Borrowings issued at fixed rates expose the Group to fair value interest rate risk. The Group currently does not use any interest rate swap contracts or other financial instruments to hedge against interest rate exposure.

Credit Risk

Credit risk is the risk regarding the loss arising from a counterparty's inability to meet its obligations. The management of the Group has put in place a credit policy and the exposure to such credit risks is monitored on an on-going basis.

Liquidity Risk

The Group's liquidity is primarily dependent on its ability to maintain adequate cash inflows from operations to meet its debt obligations as they fall due, and the ability to obtain external financing to meet its committed future capital expenditure.

The Group monitors and maintains a level of cash and cash equivalents deemed adequate by its management to finance the operation and mitigate the effects of fluctuations in cash flows.

Interim Dividends

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2025 (for the six months ended June 30, 2024: HK\$0.1307 per share).

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Since January 1, 2025 and up to the date of this announcement, save as provisions addressed below, the Company has complied with all the applicable code provisions as set out in the Corporate Governance Code (the “**CG Code**”) contained in Appendix C1 to the Listing Rules.

Code provision C.2.1 of the CG Code stipulates that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual.

The roles of chairman of the Board and chief executive officer of the Company are held by Mr. Zhang Bozhou who has extensive experience in the industry. The Board believes that vesting the roles of the chairman and chief executive officer in Mr. Zhang Bozhou is beneficial to the management of the Group and will improve the efficiency of the Group’s decision making and executive process given his knowledge in the Group’s affairs. Further, the Group has put in place an appropriate check-and-balance mechanism through the Board and the independent non-executive Directors.

In view of the above, the Board considers that such structure will not impair the balance of power and authority between the Board and the management of the Group. The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangement when the Board considers appropriate.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix C3 to the Listing Rules as its code of conduct regarding securities transactions by the Directors. Upon specific enquiry, all Directors confirmed that they had complied with the requirements as set out in the Model Code since January 1, 2025 and up to the date of this announcement.

AUDIT COMMITTEE

The Company has established the Audit Committee with written terms of reference in compliance with the requirements under the Listing Rules. The Audit Committee is composed of three independent non-executive Directors, being Mr. Li Jianbin (chairman of the Audit Committee), Ms. Guo Hongyan and Mr. Bao Shan. The primary duties of the Audit Committee are to assist the Board in providing an independent view of the effectiveness of

the financial reporting process, the internal control and risk management system of the Group, to oversee the audit process and to perform other duties and responsibilities as assigned by the Board.

PROCEEDS FROM GLOBAL OFFERING AND ITS UTILIZATION

Use of Proceeds from Global Offering

The shares of the Company were listed on the Main Board of the Stock Exchange on July 7, 2021. In the Global Offering, the Company issued 137,500,000 Shares at HK\$10.60 per share and subsequently issued 20,125,000 Shares at HK\$10.60 per share on August 3, 2021 upon partial exercise of the overallotment option. The net proceeds from the Global Offering received by the Company, after deduction of the underwriting fees and commissions and other expenses payable by the Company in connection with the Global Offering, were approximately HK\$1,599 million.

Updated Expected Timetable for Use of Proceeds and Change in Use of Proceeds from the Global Offering

As at June 30, 2025, the unutilised balance of net proceeds was approximately HK\$681.50 million. After considering, (1) The upgrade of the Company's current information technology system has been basically completed and can meet the development needs of the Company, there being no large-scale update plans for the Company's information technology system in the near term. With the efforts of the Company and its team, there is still a surplus of funds after the information system upgrade is completed. In accordance with the Company's overall strategic planning, the remaining funds from the information technology system upgrade project will be allocated to the establishment and upgrading of existing hospitals, the use of which will be extended for another two years. (2) In light of the current situation of the ophthalmology market and the Company's actual circumstances, the Company has adjusted the progress of acquiring and establishing new hospitals. The targets for hospital acquisition are still under screening, so part of the planned funds will be allocated to the establishment of new hospitals and upgrading of existing hospitals and extend it for two years. Therefore, in respect of the use of proceeds as disclosed in the Prospectus and subsequent update on the expected timeline for use of such proceeds as disclosed in the announcement of the Company dated March 26, 2024, the Board resolved on August 29, 2025 to (a) further extend the expected timetable for the use of net proceeds for two years; and (b) reallocate HK\$167.99 million from "acquiring hospitals, when appropriate opportunities arise, in new markets which has sizable population and relatively high level of demand for ophthalmic healthcare services" and HK\$60.00 million from "upgrading information technology systems" to "establishment of new hospitals and the relocation, upgrade and renovation of existing hospitals".

The Board considered the impact of the proposed change in the use of net proceeds from the Global Offering and the further extension of timeline on the Group's business and operation and believes that, in view of the Group's operation and business development, the reallocation of net proceeds and extension of timeline will facilitate efficient allocation of financial resources and strengthen the future development of the Group, and it is appropriate and in the interests of the Company and its shareholders as a whole. Save for the above, there is no other change in the use of net proceeds from the Global Offering and the expected timeline.

To strive for better business performance of the Group, the Board will continuously assess the use of unutilised net proceeds and the timetable for use of such proceeds and may revise or amend the plan for the use of net proceeds where necessary in respond to the changing market conditions.

| Intended Use of Net Proceeds | Planned Amount of the Net Proceeds for its Intended Use ^(Note 1) (HK\$ million) | Revised Allocation of the Net Proceeds for its Intended Use (HK\$ million) | Utilised Amount of Net Proceeds during the Reporting Period (HK\$ million) | Actual Utilisation up to June 30, 2025 (HK\$ million) | Unutilised Net Proceeds as at June 30, 2025 (as Revised) (HK\$ million) | Updated expected timetable for Utilisation of Unutilised Net Proceeds ^(Note 2) |
|---|---|---|---|--|---|---|
| Establishment of new hospitals and the relocation, upgrade and renovation of existing hospitals | 572.44 | 800.42 | 59.01 | 345.06 | 455.36 | expected to be fully utilized on or before December 31, 2027 |
| Acquiring hospitals, when appropriate opportunities arise, in new markets which has sizable population and relatively high level of demand for ophthalmic healthcare services | 716.35 | 548.37 | – | 360.25 | 188.12 | expected to be fully utilized on or before December 31, 2027 |
| Upgrading information technology systems | 150.31 | 90.31 | 3.64 | 52.29 | 38.02 | expected to be fully utilized on or before December 31, 2027 |
| Working capital and other general corporate purposes | 159.90 | 159.90 | – | 159.90 | – | |
| Total | 1,599.00 | 1,599.00 | 62.65 | 917.5 | 681.50 | |

Notes:

(1) Planned application of the net proceeds as disclosed in the Prospectus.

- (2) The updated expected timeline for utilizing the remaining net proceeds is made based on the best estimation of the Company taking into account, among others, the prevailing and future market conditions and business development and need, and is therefore subject to change.

As at the date of this announcement, the Company has been utilizing the net proceeds from the Global Offering in compliance with the plan as disclosed in the Prospectus and the announcement of the Company dated March 26, 2024. The unutilised portion of the net proceeds from the Global Offering will be applied in a manner consistent with the above revised plan.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

During the period from January 1, 2025 to June 30, 2025, pursuant to the share repurchase mandate approved by the Shareholders at the annual general meeting of the Company held on June 6, 2024, the Company repurchased a total of 16,000 Shares from the Stock Exchange and such Shares were held as treasury shares of the Company. Details of the repurchase are summarized as follows:

| Repurchase date | Price per share | | Number of shares | Total Consideration |
|------------------------|-------------------------------------|------------------------------------|-------------------------|----------------------------|
| | Highest price <i>HK\$</i> | Lowest price <i>HK\$</i> | | |
| March 27, 2025 | 2.69 | 2.67 | 16,000 | 42,925 |

All the repurchased Shares as mentioned above have been cancelled on April 29, 2025. The Board considers that the repurchase can benefit the Shareholders as a whole by enhancing the earnings per share.

Save as disclosed above, since January 1, 2025 and up to the date of this announcement, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale and/or transfer of treasury shares).

As at June 30, 2025 and the date of this announcement, the Group did not hold any treasury shares.

EMPLOYEES AND REMUNERATION POLICIES

As of June 30, 2025, the Group had 2,627 full-time employees, among which, 1,500 were professionals at the hospitals, 99 were professionals at the optical centers and 1,028 were administrative, finance and other employees at the Group's headquarters, hospitals and optical centers. In addition, the Group also had 74 practice physicians who were fulltime employees of other medical institutions. The following table shows a breakdown of the Group's full-time employees by function as of that date:

| | Number of employees | Percentage of total employees |
|---|--------------------------------|--|
| Professionals at the hospitals | | |
| Physicians ⁽¹⁾ | 320 | 12.18% |
| Nurses | 631 | 24.02% |
| Other professionals | 549 | 20.9% |
| Professionals at the optical centers | 99 | 3.77% |
| Administrative, finance and other employees at | | |
| The headquarters | 149 | 5.67% |
| The hospitals | 839 | 31.94% |
| The optical centers | 40 | 1.52% |
| Total | <u>2,627</u> | <u>100.00%</u> |

Note:

(1) As of June 30, 2025, 271 of the full-time physicians were registered as specialized ophthalmologists.

The Group enters into employment contracts with all of its full-time employees. The remuneration packages for its employees primarily comprise one or more of the following elements: basic salary, performance-based incentive bonus and discretionary year-end bonus. The Group also sets performance targets for its employees based on their position and regularly reviews their performances, the results of which are used in their annual salary reviews and promotion appraisals.

The Group adopted a share award scheme on May 10, 2022, for the purposes of recognizing and motivating the contribution of certain employees of the Group and incentivizing them and helping the Group in retaining its existing employees and attracting and recruiting suitable personnel as additional employees to further the operation and development of the Group and providing them with a direct economic interest in attaining the long-term business objectives of the Group. The Scheme is analogous to a share scheme and subject to provisions of Chapter 17 of the Listing Rules (as amended with effect from January 1, 2023). Further details of the Scheme are set out in the section headed "Share Schemes" in our 2025 interim report to be issued in due course.

The Group provides structured training and education programs which enables its employees to consistently deliver high quality services. The Group's discipline development committees are responsible for training its medical professionals, maintaining a proper mix of different levels of professionals, as well as research and development, and have supplied numerous young ophthalmologists with solid skills and rich clinical experience. The Group also engages external consultants, experts and professors to provide training for the physicians with an aim to cultivate clinicians with extensive practical capabilities in a precise, standardized and high-quality manner. These programs aim to equip them with a sound foundation of the medical principles, ethics and knowledge as well as practical skills, and foster a high standard of practice. Regular internal and external mandatory online and on-site training are organized for the medical team to keep them abreast of the latest development in the ophthalmology industry. From time to time, the Group identifies and sponsors its employees with high development potential to undertake further study and professional training in prestigious medical institutions. They also support their attending physicians to train at top-tier eye hospitals in China for a period of three to six months, such as Wenzhou Medical University Eye Hospital (溫州醫科大學附屬眼視光醫院). In addition, the Group also designs and implements specialized training for its nurses and medical assistants to improve their respective professional skills and foster their professional career path.

As of June 30, 2025, none of the Group's employees had negotiated with them on the employment terms through the labor unions or in a way of collective bargaining and the Group had not experienced any major labor disputes or labor strikes that had interfered with its operations in any material respect.

REVIEW OF INTERIM RESULTS

The independent auditors of the Company, namely Ernst & Young, have carried out a review of the interim financial information in accordance with the Hong Kong Standard on Review Engagement 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants. The Audit Committee has jointly reviewed with the management and the independent auditors of the Company, the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results for the six months ended June 30, 2025) of the Group. The Audit Committee and the independent auditors considered that the interim results are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

EVENTS AFTER THE REPORTING PERIOD

On July 28, 2025, Inner Mongolia Chaoju Medical Technology Co., Ltd.* (內蒙古朝聚醫療科技有限責任公司), an indirect wholly-owned subsidiary of the Company, entered into a construction contract with Inner Mongolia Guangxia Construction & Installation Engineering Co., Ltd.* (內蒙古廣廈建安工程有限責任公司) in relation to the construction of the Chaoju Eye Care Integrated Medical Complex Construction Project Phase I at a contract price of RMB222.84 million (inclusive of tax) (the “**Transaction**”), which constitutes a discloseable transaction of the Company. For further details of the Transaction, please refer to the announcement of the Company dated July 28, 2025.

On August 22, 2025, Chaoju Medical Technology Co., Ltd.* (朝聚醫療科技有限公司), an indirect wholly-owned subsidiary of the Company, subscribed for wealth management products in the principal amount of RMB30 million in total offered by BOC, which constituted a discloseable transaction of the Company. For details, please refer to the announcement of the Company dated August 22, 2025.

Save as disclosed above, there is no other significant event that might affect the Group after the Reporting Period.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND THE INTERIM REPORT ON THE WEBSITES OF THE STOCK EXCHANGE AND THE COMPANY

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.chaojueye.com), and the 2025 interim report containing all the information required by the Listing Rules will be published on the respective websites of the Stock Exchange and the Company in due course.

The Board is pleased to announce the condensed consolidated interim results of the Group for the six months ended June 30, 2025 together with the comparative figures for the same period in 2024:

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2025

| | | For the six months ended 30 June | |
|---|-------|-------------------------------------|------------------------|
| | | 2025 | 2024 |
| | Notes | RMB'000 (Unaudited) | RMB'000 (Unaudited) |
| REVENUE | 4 | 698,258 | 734,287 |
| Cost of sales | | <u>(400,591)</u> | <u>(398,313)</u> |
| Gross profit | | 297,667 | 335,974 |
| Other income and gains | | 37,833 | 25,674 |
| Selling and distribution expenses | | (48,755) | (62,976) |
| Administrative expenses | | (102,167) | (106,437) |
| Impairment losses on financial assets at amortised cost, net | | (353) | (534) |
| Other expenses | | (25,031) | (6,443) |
| Finance costs | | <u>(6,104)</u> | <u>(5,618)</u> |
| PROFIT BEFORE TAX | 5 | 153,090 | 179,640 |
| Income tax expense | 6 | <u>(42,351)</u> | <u>(46,020)</u> |
| PROFIT FOR THE PERIOD | | <u>110,739</u> | <u>133,620</u> |
| Attributable to: | | | |
| Owners of the parent | | 113,643 | 136,453 |
| Non-controlling interests | | <u>(2,904)</u> | <u>(2,833)</u> |
| | | <u>110,739</u> | <u>133,620</u> |
| EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT | 8 | | |
| Basic (in RMB per share) | | <u>0.16</u> | <u>0.20</u> |
| Diluted (in RMB per share) | | <u>0.16</u> | <u>0.20</u> |

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2025

| | For the six months ended 30 June | |
|---|-------------------------------------|-----------------------|
| | 2025 | 2024 |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| | (Unaudited) | (Unaudited) |
| PROFIT FOR THE PERIOD | <u>110,739</u> | <u>133,620</u> |
| OTHER COMPREHENSIVE INCOME | | |
| Other comprehensive income that may be reclassified to profit or loss in subsequent periods: | | |
| Exchange differences on translation of foreign operations | <u>(9,704)</u> | <u>4,352</u> |
| TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | <u>101,035</u> | <u>137,972</u> |
| Attributable to: | | |
| Owners of the parent | 103,939 | 140,805 |
| Non-controlling interests | <u>(2,904)</u> | <u>(2,833)</u> |
| | <u>101,035</u> | <u>137,972</u> |

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
30 June 2025

| | | 30 June 2025 | 31 December 2024 |
|---|--------------|-------------------------|-----------------------------|
| | <i>Notes</i> | RMB'000 | RMB'000 |
| | | (Unaudited) | (Audited) |
| NON-CURRENT ASSETS | | | |
| Property, plant and equipment | | 463,916 | 391,917 |
| Investment properties | | 26,736 | 27,415 |
| Right-of-use assets | | 266,253 | 241,273 |
| Goodwill | | 167,231 | 185,599 |
| Intangible assets | | 155,969 | 165,635 |
| Financial assets at fair value through profit or loss | | 124,488 | 125,337 |
| Deferred tax assets | | 9,300 | 7,664 |
| Time deposits | | 70,938 | 20,339 |
| Prepayments, other receivables and other assets | | 66,732 | 7,753 |
| Pledged deposits | | 5,607 | – |
| Total non-current assets | | 1,357,170 | 1,172,932 |
| CURRENT ASSETS | | | |
| Inventories | | 47,098 | 40,313 |
| Trade receivables | 9 | 70,290 | 74,426 |
| Prepayments, other receivables and other assets | | 51,210 | 52,983 |
| Financial assets at fair value through profit or loss | | 415,376 | 462,068 |
| Other current financial assets | | – | 10,092 |
| Time deposits | | 775,498 | 287,317 |
| Cash and cash equivalents | | 283,790 | 780,785 |
| Total current assets | | 1,643,262 | 1,707,984 |
| CURRENT LIABILITIES | | | |
| Trade payables | 10 | 64,104 | 53,614 |
| Other payables and accruals | | 265,960 | 229,172 |
| Due to related parties | | 22 | 22 |
| Interest-bearing bank and other borrowings | | 6,704 | 7,073 |
| Lease liabilities | | 37,665 | 34,251 |
| Tax payable | | 19,136 | 15,153 |
| Total current liabilities | | 393,591 | 339,285 |
| NET CURRENT ASSETS | | 1,249,671 | 1,368,699 |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | 2,606,841 | 2,541,631 |

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(continued)
30 June 2025

| | 30 June 2025 RMB'000 (Unaudited) | 31 December 2024 RMB'000 (Audited) |
|--|---|---|
| NON-CURRENT LIABILITIES | | |
| Convertible bonds | 34,278 | 33,556 |
| Lease liabilities | 175,115 | 143,126 |
| Deferred tax liabilities | 33,706 | 36,953 |
| Other payables and accruals | 1,845 | 1,845 |
| | <hr/> | <hr/> |
| Total non-current liabilities | 244,944 | 215,480 |
| | <hr/> | <hr/> |
| Net assets | 2,361,897 | 2,326,151 |
| | <hr/> <hr/> | <hr/> <hr/> |
| EQUITY | | |
| Equity attributable to owners of the parent | | |
| Share capital | 152 | 152 |
| Treasury shares | (45,043) | (63,963) |
| Equity component of convertible bonds | 947 | 947 |
| Reserves | 2,398,384 | 2,379,054 |
| | <hr/> | <hr/> |
| | 2,354,440 | 2,316,190 |
| | <hr/> | <hr/> |
| Non-controlling interests | 7,457 | 9,961 |
| | <hr/> | <hr/> |
| Total equity | 2,361,897 | 2,326,151 |
| | <hr/> <hr/> | <hr/> <hr/> |

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2025

| | | For the six months ended 30 June | |
|--|-------|-------------------------------------|----------------|
| | | 2025 | 2024 |
| | Notes | RMB'000 | RMB'000 |
| | | (Unaudited) | (Unaudited) |
| CASH FLOWS FROM OPERATING ACTIVITIES | | | |
| Profit before tax | | 153,090 | 179,640 |
| Adjustments for: | | | |
| Finance costs | | 6,104 | 5,618 |
| Interest income | | (18,462) | (22,540) |
| Foreign exchange differences, net | 5 | (2,219) | 3,380 |
| Fair value gains on financial assets at fair value through profit or loss | 5 | (4,271) | (567) |
| Depreciation of property, plant and equipment | 5 | 37,236 | 36,781 |
| Depreciation of investment properties | 5 | 679 | 679 |
| Depreciation of right-of-use assets | 5 | 28,579 | 28,611 |
| Amortisation of intangible assets | 5 | 7,210 | 6,596 |
| Impairment loss of trade receivables, net | 5 | 412 | 594 |
| Reversal of impairment loss on other receivables | 5 | (59) | (60) |
| Impairment of intangible assets | 5 | 4,381 | – |
| Impairment of goodwill | 5 | 18,368 | – |
| (Gain)/loss on disposal of items of property, plant and equipment, net | 5 | (79) | 32 |
| Gain on modification of leases | 5 | (1,253) | – |
| Share-based payments | | 7,662 | 11,133 |
| | | 237,378 | 249,897 |
| Increase in inventories | | (6,785) | (4,187) |
| Decrease/(increase) in trade receivables | | 3,724 | (12,376) |
| Decrease/(increase) in prepayments, other receivables and other assets | | 3,282 | (3,466) |
| Increase in trade payables | | 10,490 | 7,215 |
| Decrease in other payables and accruals | | (18,713) | (18,263) |
| Decrease in amounts due to related parties | | – | (284) |
| Increase in pledged deposits | | (5,607) | – |
| Cash generated from operations | | 223,769 | 218,536 |
| Interest received | | 6,260 | 5,567 |
| Interest paid | | (5,224) | (5,461) |
| Income tax paid | | (43,251) | (44,181) |
| Net cash flows from operating activities | | 181,554 | 174,461 |

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (continued)*For the six months ended 30 June 2025*

| | For the six months ended 30 June | |
|--|---|--------------------|
| | 2025 | 2024 |
| | RMB'000 | RMB'000 |
| | (Unaudited) | (Unaudited) |
| CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Purchases of financial assets at fair value through profit or loss | (200,000) | (540,000) |
| Proceeds from disposal of financial assets at fair value through profit or loss | 251,812 | 565,634 |
| Placement of time deposits with original maturity over three months | (644,458) | (245,402) |
| Withdrawal of time deposits with original maturity over three months | 116,650 | 241,453 |
| Purchases of other current financial assets | (30,000) | – |
| Redemption of other current financial assets | 40,269 | 50,604 |
| Purchases of items of property, plant and equipment | (112,053) | (30,359) |
| Purchases of intangible assets | (1,927) | (3,253) |
| Payments for acquisition of other assets | – | (40,945) |
| Proceeds from disposal of items of property, plant and equipment | 490 | 64 |
| Payment for acquisition of subsidiaries in prior years | – | (16,587) |
| Net cash flows used in investing activities | <u>(579,217)</u> | <u>(18,791)</u> |
| CASH FLOWS FROM FINANCING ACTIVITIES | | |
| Purchases of shares for share award scheme | (40) | (2,690) |
| Prepayments received from the award of shares under the share award scheme | 2,121 | 4,364 |
| Repurchase of restricted shares under the share award scheme | (419) | (191) |
| Repayment of interest-bearing bank and other borrowings | (527) | (380) |
| Principal portion of lease payments | (16,904) | (38,317) |
| Dividends paid | (75,981) | (187,134) |
| Acquisition of non-controlling interests | <u>(1,150)</u> | <u>–</u> |
| Net cash flows used in financing activities | <u>(92,900)</u> | <u>(224,348)</u> |

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (continued)*For the six months ended 30 June 2025*

| | For the six months ended 30 June | |
|--|---|--------------------|
| | 2025 | 2024 |
| | RMB'000 | RMB'000 |
| | (Unaudited) | (Unaudited) |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | (490,563) | (68,678) |
| Cash and cash equivalents at beginning of period | 780,785 | 463,437 |
| Effect of foreign exchange rate changes, net | (6,432) | 975 |
| | <hr/> | <hr/> |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | 283,790 | 395,734 |
| | <hr/> | <hr/> |
| ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS | | |
| Cash and bank balances | 283,790 | 395,734 |
| | <hr/> | <hr/> |
| Cash and cash equivalents as stated in the interim condensed consolidated statement of cash flows | 283,790 | 395,734 |
| | <hr/> | <hr/> |

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2025

1. CORPORATE INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on 19 May 2020. The registered office address of the Company is Level 20, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong.

The Company is an investment holding company. The Company's subsidiaries are involved in the provision of in-patient services, out-patient services, sales of optical products and sales of equipment and medical consumables in the mainland of the People's Republic of China (the "PRC").

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

2.1 BASIS OF PRESENTATION

The interim condensed consolidated financial information of the Group for the six months ended 30 June 2025 has been prepared in accordance with International Accounting Standard ("IAS") 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2024.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended IFRS Accounting Standard for the first time for the current period's financial information.

Amendments to IAS 21 *Lack of Exchangeability*

The nature and impact of the amended IFRS Accounting Standard are described below:

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

The Group is principally engaged in the provision of in-patient services, out-patient services, sales of optical products and sales of equipment and medical consumables. For management purposes, the aforesaid businesses are integral and the Group has not organized into different operating segments. Management monitors the results of the Group's operation as a whole for the purpose of making decisions about resource allocation and performance assessment, and accordingly no further operating segment analysis thereof is presented.

Geographical information

As the Group's major operations, customers and non-current assets are located in the PRC, no further geographical segment information is provided.

Information about major customers

No revenue from single customers individually accounted for 10% or more of the Group's revenue.

4. REVENUE

An analysis of revenue is as follows:

| | For the six months ended 30 June | |
|--|--------------------------------------|--------------------------------------|
| | 2025 | 2024 |
| | <i>RMB'000</i> (Unaudited) | <i>RMB'000</i> (Unaudited) |
| Revenue from contracts with customers | 698,258 | 734,287 |
| Analysed into: | | |
| Consumer ophthalmic services | 359,492 | 376,483 |
| Basic ophthalmic services | 337,467 | 357,214 |
| Sales of equipment and medical consumables | 1,299 | 590 |
| Total | 698,258 | 734,287 |

(a) **Disaggregated revenue information for revenue from contracts with customers**

| | For the six months ended 30 June | |
|---|---|-----------------------|
| | 2025 | 2024 |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| | (Unaudited) | (Unaudited) |
| Types of goods or services | | |
| Out-patient services | 416,180 | 436,163 |
| In-patient services | 233,052 | 252,569 |
| Sales of optical products | 47,727 | 44,965 |
| Sales of equipment and medical consumables | 1,299 | 590 |
| | <hr/> | <hr/> |
| Total | 698,258 | 734,287 |
| | <hr/> <hr/> | <hr/> <hr/> |
| | For the six months ended 30 June | |
| | 2025 | 2024 |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| | (Unaudited) | (Unaudited) |
| Timing of revenue recognition | | |
| Services and goods transferred at a point in time | 465,206 | 481,718 |
| Services transferred over time | 233,052 | 252,569 |
| | <hr/> | <hr/> |
| Total | 698,258 | 734,287 |
| | <hr/> <hr/> | <hr/> <hr/> |

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

| | For the six months ended 30 June | |
|---|----------------------------------|----------------|
| | 2025 | 2024 |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| | (Unaudited) | (Unaudited) |
| Depreciation of property, plant and equipment | 37,236 | 36,781 |
| Depreciation of investment properties | 679 | 679 |
| Depreciation of right-of-use assets | 28,579 | 28,611 |
| Amortisation of intangible assets | 7,210 | 6,596 |
| Impairment loss on trade receivables, net | 412 | 594 |
| Reversal of impairment loss on other receivables | (59) | (60) |
| Impairment of intangible assets [#] | 4,381 | – |
| Impairment of goodwill [#] | 18,368 | – |
| Fair value gains on financial assets at fair value through profit or loss | (4,271) | (567) |
| (Gain)/loss on disposal of items of property, plant and equipment, net | (79) | 32 |
| Gain on modification of leases | (1,253) | – |
| Foreign exchange differences, net | (2,219) | 3,380 |

[#] Included in other expenses on the face of the interim condensed consolidated statement of profit or loss.

6. INCOME TAX EXPENSE

Pursuant to Caishui [2020] No.23 “Announcement Regarding Continuation of Corporate Tax Policies for the Development of the Western Region” (關於延續西部大開發企業所得稅政策的公告), certain subsidiaries operated in the western region of Mainland China are entitled to a preferential corporate income tax rate of 15%, provided that the main business of the subsidiaries belongs to the encouraged projects stipulated in the Catalogue of Encouraged Industries in the Western Region, and such main business income accounts for more than 60% of the total income of the subsidiaries.

Pursuant to Caishui [2022] No.13 “Announcement on Further Implementing the Income Tax Preferential Policies for Small Meagre-profit Enterprises” (關於進一步實施小微企業所得稅優惠政策的公告), from 1 January 2022 to 31 December 2024, certain subsidiaries for the portion of taxable income exceeding RMB1,000,000 but not exceeding RMB3,000,000, the amount of taxable income can be halved 25%, and the income tax rate will be levied at 20%.

Pursuant to Caishui [2023] No.6 “Announcement on the Income Tax Preferential Policies for Small Meagre-profit Enterprises and Self-employed Businesses” (關於小微企業和個體工商戶所得稅優惠政策的公告), from 1 January 2023 to 31 December 2024, certain subsidiaries for the portion of taxable income not exceeding RMB1,000,000, the amount of taxable income can be halved 25%, and the income tax rate will be levied at 20%.

Pursuant to Caishui [2023] No.12 “Announcement on Relevant Tax and Fee Policies for Further Supporting the Development of Small Meagre-profit Enterprises and Self-employed Businesses” (關於進一步支持小微企業和個體工商戶發展有關稅費政策的公告), the policy of halving the taxable income of small meagre-profit enterprises and self-employed businesses at 25% and levying enterprise income tax at a rate of 20% will be extended until December 31, 2027.

Pursuant to Neishuifa [2024] No.1 “Several Measures by the Taxation Bureau of Inner Mongolia Autonomous Region to Further Support the High-Quality Development of the Private Economy” (內蒙古自治區稅務局進一步支持民營經濟高質量發展的若干措施), effective from 3 January 2024, for small meagre-profit enterprises with an annual taxable income of less than RMB1 million, the local share portion of corporate income tax is exempted.

Under the relevant PRC Corporate Income Tax Law and the respective regulations, except for the preferential treatments available to certain subsidiaries as mentioned above, other subsidiaries within the Group were subject to corporate income tax at the statutory rate of 25%.

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands, the Group is not subject to any income tax in the Cayman Islands and the British Virgin Islands.

No provision for Hong Kong profits tax has been made as the Group had no assessable profits derived from or earned in Hong Kong for the six months ended 30 June 2025 (six months ended 30 June 2024: Nil).

| | For the six months ended 30 June | |
|-----------------------|---|-----------------------|
| | 2025 | 2024 |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| | (Unaudited) | (Unaudited) |
| Current – PRC | | |
| Charge for the period | 47,234 | 52,837 |
| Deferred | (4,883) | (6,817) |
| Total | 42,351 | 46,020 |

7. DIVIDENDS

| | 30 June 2025 RMB'000 (Unaudited) | 30 June 2024 RMB'000 (Unaudited) |
|--|---|---|
| Final 2024 declared and paid – HK11.93 cents (Final 2023: HK22.08 cents) per ordinary share | 77,292 | 142,256 |
| Special declared and paid – HK0 cents (Special 2023: HK7.67 cents) per ordinary share | – | 49,416 |
| Less: Dividend for shares held under the share award scheme | <u>(1,311)</u> | <u>(4,538)</u> |
| Total | <u>75,981</u> | <u>187,134</u> |

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2025 (six months ended 30 June 2024: HK13.07 cents per ordinary share, amounting approximately HK\$92,444,000).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 691,616,000 (30 June 2024: 687,682,000) outstanding during the period.

The calculation of the diluted earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise or conversion of all dilutive potential ordinary shares into ordinary shares.

No adjustment has been made to the basic earnings per share amount in respect of a dilution as the impact of the convertible bonds had no dilutive effect on the basic earnings per share.

The calculations of basic and diluted earnings per share are based on:

| | For the six months ended 30 June | |
|--|---|-----------------------|
| | 2025 | 2024 |
| | <i>RMB'000</i> | <i>RMB'000</i> |
| | (Unaudited) | (Unaudited) |
| Earnings | | |
| Profit for the period attributable to ordinary equity holders of the parent used in the basic and diluted earnings per share calculation | <u>113,643</u> | <u>136,453</u> |
| Total | <u><u>113,643</u></u> | <u><u>136,453</u></u> |
| Number of shares | | |
| | For the six months ended 30 June | |
| | 2025 | 2024 |
| | <i>'000</i> | <i>'000</i> |
| | (Unaudited) | (Unaudited) |
| Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation | <u>691,616 *</u> | <u>687,682*</u> |
| Total | <u><u>691,616</u></u> | <u><u>687,682</u></u> |

* The weighted average number of shares was after taking into account the effect of treasury shares held.

9. TRADE RECEIVABLES

An ageing analysis of the trade receivables at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

| | 30 June 2025 <i>RMB'000</i> (Unaudited) | 31 December 2024 <i>RMB'000</i> (Audited) |
|-----------------|--|--|
| Within 3 months | 42,202 | 51,250 |
| 4 to 6 months | 9,081 | 7,582 |
| 7 to 12 months | 11,291 | 9,297 |
| Over 12 months | 7,716 | 6,297 |
| | <hr/> | <hr/> |
| Total | 70,290 | 74,426 |
| | <hr/> <hr/> | <hr/> <hr/> |

10. TRADE PAYABLES

An ageing analysis of trade payables as at the end of the reporting period, based on the invoice date, is as follows:

| | 30 June 2025 <i>RMB'000</i> (Unaudited) | 31 December 2024 <i>RMB'000</i> (Audited) |
|---------------|--|--|
| Within 1 year | 56,684 | 47,937 |
| 1 to 2 years | 3,080 | 2,424 |
| 2 to 3 years | 2,511 | 1,252 |
| Over 3 years | 1,829 | 2,001 |
| | <hr/> | <hr/> |
| Total | 64,104 | 53,614 |
| | <hr/> <hr/> | <hr/> <hr/> |

GLOSSARY AND DEFINITIONS

| | |
|----------------------|---|
| “Audit Committee” | the audit committee of the Board |
| “Board” | the board of Directors |
| “BOC” | Bank of China Limited |
| “cataract” | a condition involving the clouding or opacification of the natural lens. Cataract is most commonly caused by aging, but may also be caused by other reasons such as malnutrition, diabetes, trauma or radiation. The opaquer the lens the more the quality of vision is reduced. As a common treatment, clear artificial lenses may be implanted as a substitute for the natural lens to restore clear vision |
| “China” or the “PRC” | the People’s Republic of China, but for the purpose of this announcement and for geographical reference only, references herein to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan |
| “Company” | Chaoju Eye Care Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands on May 19, 2020 |
| “Director(s)” | director(s) of the Company |
| “East China” | an eastern region of China consisting of Hangzhou, Zhoushan and Zhejiang Province |
| “glaucoma” | an eye condition usually caused by overly high intraocular pressure, which usually causes optic nerve atrophies and visual field defect |
| “Global Offering” | the Hong Kong Public Offering and the International Offering |
| “Group” | the Company together with its subsidiaries |
| “HK\$” | Hong Kong dollars and cents respectively, the lawful currency of Hong Kong |
| “Hong Kong” | the Hong Kong Special Administrative Region of the PRC |

| | |
|-----------------------|--|
| “IFRS” | the International Financial Reporting Standards |
| “Inner Mongolia” | the Inner Mongolia Autonomous Region of the PRC, unless the context indicates otherwise |
| “in-patient services” | treatments of patients who are checked in at hospitals and are hospitalized overnight or for an extended period of time |
| “IPO Proceeds” | the proceeds obtained by the Company from the Global Offering |
| “Listing Rules” | the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time |
| “Main Board” | the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the GEM of the Stock Exchange |
| “myopia” | a type of refractive error also known as nearsightedness, where the patient is unable to see distant objects clearly. Myopia is usually caused by a longer-than-normal eyeball or excessive refractive ability of the crystalline lens, which results in parallel lights focusing at a position before reaching the retina, thus forming a blurred spot when it reaches the retina |
| “North China” | a northern region of China consisting of Beijing, Tianjin, Hebei Province, Shanxi Province and Inner Mongolia |
| “ocular fundus” | the interior surface of the eye opposite the crystalline lens, including the retina, optic disc, macula and posterior pole |
| “ocular surface” | the interface between the functioning eye and the environment, including the outer layer of the cornea, the conjunctiva, and the margin of the eye lids |
| “oculoplastic” | restorative or reconstructive surgeries performed near or around the eye to correct deformations caused by trauma, illness or congenital causes |
| “ophthalmologist” | a medical doctor who specializes in eye and vision care |

| | |
|------------------------|--|
| “out-patient services” | treatments of patients who are not checked-in at hospitals and stay at the hospital only for a short period of time (usually completed within the day) |
| “presbyopia” | an eye condition where the patient has difficulty seeing near items clearly due to declines in refractive abilities of the lens. Presbyopia is a result of the aging of the eye, as the lens loses its natural elasticity and therefore its ability to focus on near objects |
| “Prospectus” | the prospectus of the Company published on June 24, 2021 |
| “Reporting Period” | the six months ended June 30, 2025 |
| “RMB” | the lawful currency of the PRC |
| “Scheme” | the share award scheme of the Company as adopted by the Board on May 10, 2022 and as amended from time to time |
| “Share(s)” | ordinary share(s) in the share capital of the Company with nominal value of HK\$0.00025 each |
| “Shareholder(s)” | holder(s) of the Shares |
| “squint” | deviation of the eyes where there is an eye misalignment |
| “Stock Exchange” | the Stock Exchange of Hong Kong Limited |

By order of the Board
Chaoju Eye Care Holdings Limited
ZHANG Bozhou
Chairman

Hong Kong, August 29, 2025

As of the date of this announcement, the board of directors of the Company comprises Mr. ZHANG Bozhou as the chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. Richard Chen MAO, Mr. LI Zhen and Ms. ZHANG Li as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.

* The English translation of the Chinese names denoted in this announcement is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.